WO2003027151A1 - Anticorps recombinant anti-osteopontine et son utilisation - Google Patents

Anticorps recombinant anti-osteopontine et son utilisation Download PDF

Info

Publication number
WO2003027151A1
WO2003027151A1 PCT/JP2002/009868 JP0209868W WO03027151A1 WO 2003027151 A1 WO2003027151 A1 WO 2003027151A1 JP 0209868 W JP0209868 W JP 0209868W WO 03027151 A1 WO03027151 A1 WO 03027151A1
Authority
WO
WIPO (PCT)
Prior art keywords
rheumatism
osteopontin
antibody
remedy
inhibits
Prior art date
Application number
PCT/JP2002/009868
Other languages
English (en)
French (fr)
Inventor
Toshimitsu Uede
Shigeyuki Kon
Nobuchika Yamamoto
Hirofumi Higuchi
Masaharu Torikai
Yoshiyuki Tokieda
Toshihiro Nakashima
Hiroaki Maeda
Original Assignee
Immuno-Biological Laboratories Co., Ltd.
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR10-2004-7004266A priority Critical patent/KR20040048899A/ko
Application filed by Immuno-Biological Laboratories Co., Ltd., Fujisawa Pharmaceutical Co., Ltd. filed Critical Immuno-Biological Laboratories Co., Ltd.
Priority to AU2002332290A priority patent/AU2002332290B2/en
Priority to HU0402049A priority patent/HUP0402049A3/hu
Priority to CA002461529A priority patent/CA2461529A1/en
Priority to NZ531818A priority patent/NZ531818A/en
Priority to EP02768058A priority patent/EP1431310A4/en
Priority to US10/489,866 priority patent/US7241873B2/en
Priority to JP2003530737A priority patent/JPWO2003027151A1/ja
Priority to BR0213078-5A priority patent/BR0213078A/pt
Priority to MXPA04002837A priority patent/MXPA04002837A/es
Publication of WO2003027151A1 publication Critical patent/WO2003027151A1/ja
Priority to NO20041225A priority patent/NO20041225L/no
Priority to HK06104204A priority patent/HK1084127A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/JP2002/009868 2001-09-25 2002-09-25 Anticorps recombinant anti-osteopontine et son utilisation WO2003027151A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP02768058A EP1431310A4 (en) 2001-09-25 2002-09-25 ANTI-OSTEOPONTIN RECOMBINANT ANTIBODY AND USE THEREOF
AU2002332290A AU2002332290B2 (en) 2001-09-25 2002-09-25 Recombinant anti-osteopontin antibody and use thereof
HU0402049A HUP0402049A3 (en) 2001-09-25 2002-09-25 Recombinant anti-osteopontin antibody and use thereof
CA002461529A CA2461529A1 (en) 2001-09-25 2002-09-25 Recombinant anti-osteopontin antibody and use thereof
NZ531818A NZ531818A (en) 2001-09-25 2002-09-25 Recombinant anti-osteopontin antibody and use in the treatment of autoimmune diseases such as rheumatoid arthritis and osteoarthritis
KR10-2004-7004266A KR20040048899A (ko) 2001-09-25 2002-09-25 재조합 항-오스테오폰틴 항체 및 그의 용도
US10/489,866 US7241873B2 (en) 2001-09-25 2002-09-25 Recombinant anti-osteopontin antibody and use thereof
MXPA04002837A MXPA04002837A (es) 2001-09-25 2002-09-25 Anticuerpo de anti-osteopontina recombinante y uso del mismo.
BR0213078-5A BR0213078A (pt) 2001-09-25 2002-09-25 Anticorpo recombinante anti-osteopontina e uso do mesmo
JP2003530737A JPWO2003027151A1 (ja) 2001-09-25 2002-09-25 組換え抗オステオポンチン抗体およびその用途
NO20041225A NO20041225L (no) 2001-09-25 2004-03-23 Rekombinant anti-osteopontinantistoff og anvendelse derav
HK06104204A HK1084127A1 (en) 2001-09-25 2006-04-06 Recombinant anti-osteopontin antibody and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001290700 2001-09-25
JP2001-290700 2001-09-25

Publications (1)

Publication Number Publication Date
WO2003027151A1 true WO2003027151A1 (fr) 2003-04-03

Family

ID=19112969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009868 WO2003027151A1 (fr) 2001-09-25 2002-09-25 Anticorps recombinant anti-osteopontine et son utilisation

Country Status (16)

Country Link
US (1) US7241873B2 (ja)
EP (1) EP1431310A4 (ja)
JP (1) JPWO2003027151A1 (ja)
KR (1) KR20040048899A (ja)
CN (1) CN100352844C (ja)
AU (1) AU2002332290B2 (ja)
BR (1) BR0213078A (ja)
CA (1) CA2461529A1 (ja)
HK (1) HK1084127A1 (ja)
HU (1) HUP0402049A3 (ja)
MX (1) MXPA04002837A (ja)
NO (1) NO20041225L (ja)
NZ (1) NZ531818A (ja)
PL (1) PL369446A1 (ja)
RU (1) RU2305111C2 (ja)
WO (1) WO2003027151A1 (ja)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103403A1 (ja) * 2003-05-23 2004-12-02 Immuno-Biological Laboratories Co., Ltd. 免疫担当細胞活性化阻害剤およびその用途
JP2007524100A (ja) * 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー 抗ｃｃｐおよび血清アミロイドａの測定による慢性関節リウマチの評価方法
JP2007524101A (ja) * 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー リウマチ因子およびインターロイキン６の測定による慢性関節リウマチの評価方法
WO2007139164A1 (ja) 2006-05-31 2007-12-06 Astellas Pharma Inc. ヒト化抗ヒトオステオポンチン抗体
WO2008050907A1 (en) * 2006-10-26 2008-05-02 Gene Techno Science Co., Ltd. Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same
JP2008539700A (ja) * 2005-05-04 2008-11-20 オーストラリアン ステム セル センター リミテッド 系統拘束された造血幹細胞の選択、培養および作出法
WO2009088065A1 (ja) 2008-01-11 2009-07-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト化抗ヒトα９インテグリン抗体
WO2009131256A1 (en) * 2008-04-24 2009-10-29 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
US20100317587A1 (en) * 2007-06-05 2010-12-16 Seoul National University Industry Foundation Injectable bone regeneration gel containing bone formation enhancing peptide
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
WO2011037271A1 (en) * 2009-09-24 2011-03-31 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
EP2369348A1 (en) * 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
JP2014223079A (ja) * 2007-07-13 2014-12-04 バク アイピー ベスローテン フェンノートシャップ 哺乳動物ＩｇＧと結合する単一ドメイン抗原結合タンパク質

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60229509D1 (de) * 2001-04-05 2008-12-04 Astellas Pharma Inc Anti-osteopontin-antikörper und dessen verwendung
KR20040048899A (ko) 2001-09-25 2004-06-10 가부시키가이샤 멘에키세이부츠 켄큐죠 재조합 항-오스테오폰틴 항체 및 그의 용도
WO2004013311A2 (en) * 2002-08-06 2004-02-12 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
MX2009010400A (es) 2007-03-30 2010-02-18 Chu Sainte Justine Método para la determinacion de riesgo de escoliosis.
AU2008334976B2 (en) * 2007-12-13 2013-05-23 Monsanto Technology Llc Compositions and methods for early pregnancy diagnosis
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
MX2010011955A (es) * 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2010013239A (es) * 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
NZ589436A (en) * 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102149825B (zh) * 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
CN102325796B (zh) * 2009-02-23 2014-07-16 株式会社遗传科技 抗人α9整合素抗体及其用途
BRPI1012195A2 (pt) * 2009-05-01 2018-04-24 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2013507928A (ja) * 2009-10-15 2013-03-07 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012018790A2 (en) 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US20120263722A1 (en) * 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
AU2012262465A1 (en) 2011-05-27 2013-12-12 Kalobios Pharmaceuticals, Inc. Anti-EMR1 antibodies
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
ES2886443T3 (es) * 2014-08-06 2021-12-20 Astellas Pharma Inc Nuevo anticuerpo anti-Ig(beta) humana
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10349259B2 (en) * 2016-09-23 2019-07-09 Apple Inc. Broadcasting a device state in a wireless communication network
CA3146092A1 (en) * 2019-08-09 2021-02-18 Timothy MYLES Therapeutic antibodies against osteopontin
CN115558015B (zh) * 2022-10-12 2024-01-19 生工生物工程（上海）股份有限公司 一种从gst融合蛋白酶切后的产物中纯化无gst标签的目的蛋白的方法和产品

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US125023A (en) * 1872-03-26 Improvement in sand dredging-machines
US239400A (en) * 1881-03-29 Tobacco-fork
US171358A (en) * 1875-12-21 Improvement in machines for trimming and punching roofing-slates
US1408113A (en) * 1921-01-28 1922-02-28 Mason Richard Colbert Well-measuring device
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
PT690132E (pt) 1993-03-11 2004-04-30 Juridical Fou The Chemo Sero T Anticorpo monoclonal anti-hiv
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
EP0705842A2 (en) 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
CA2263942A1 (en) 1996-08-22 1998-02-26 Children's Medical Center Corporation Novel osteopontin derived chemotactic peptides and methods of use
WO1998008379A1 (en) 1996-08-27 1998-03-05 Dana-Farber Cancer Institute Methods for identifying modulators of cellular interactions mediated by osteopontin
WO1998056405A1 (en) 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
WO1999008730A1 (en) 1997-08-15 1999-02-25 Children's Medical Center Corporation Osteopontin coated surfaces and methods of use
DE69828574T2 (de) * 1997-11-14 2005-10-06 Sankyo Co., Ltd. Transgenes Tier als Modell für Allergie und seine Verwendung
US6414219B1 (en) 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
BR0009767A (pt) 1999-04-15 2002-04-30 Childrens Medical Center Agentes inibitórios e quimiotáticos derivados de osteopontina e seus usos
IL145891A0 (en) 1999-04-15 2002-07-25 Childrens Medical Center Methods and compositions for modulating an immune response
EP1269196B1 (en) * 2000-03-23 2007-11-21 Glaxo Group Limited Method of screening for inhibitors of osteopontin
WO2002032940A2 (en) 2000-10-18 2002-04-25 Children's Medical Center Corporation Osteopontin-coated surfaces and methods of use
DE60229509D1 (de) 2001-04-05 2008-12-04 Astellas Pharma Inc Anti-osteopontin-antikörper und dessen verwendung
JPWO2003008584A1 (ja) 2001-07-19 2004-11-11 財団法人化学及血清療法研究所 ヒト型抗ヒトＩｇＥ受容体抗体及び抗体フラグメント
KR20040048899A (ko) 2001-09-25 2004-06-10 가부시키가이샤 멘에키세이부츠 켄큐죠 재조합 항-오스테오폰틴 항체 및 그의 용도
WO2003046135A2 (en) 2001-11-21 2003-06-05 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
CN103518888A (zh) * 2013-10-14 2014-01-22 李民庆 一种养心宁神茶配方

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAUTISTA D.S. ET AL.: "Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin", J. BIOL. CHEM., vol. 269, no. 37, 1994, pages 23280 - 23285, XP002961002 *
JONES P.T. ET AL.: "Replacing the complementarity-determining regions in a human antibody with those from a mouse", NATURE, vol. 321, 1986, pages 522 - 525, XP002936313 *
KON S. ET AL.: "Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences", J. CELL BIOCHEM., vol. 84, no. 2, 2001, pages 420 - 432, XP002961001 *
See also references of EP1431310A4 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103403A1 (ja) * 2003-05-23 2004-12-02 Immuno-Biological Laboratories Co., Ltd. 免疫担当細胞活性化阻害剤およびその用途
EP1637159A4 (en) * 2003-05-23 2009-01-21 Immuno Biological Lab Co Ltd IMMUNOMETIMENT CELL ACTIVATION INHIBITOR AND ITS USE
EP2369348A1 (en) * 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
JP2007524100A (ja) * 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー 抗ｃｃｐおよび血清アミロイドａの測定による慢性関節リウマチの評価方法
JP2007524101A (ja) * 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー リウマチ因子およびインターロイキン６の測定による慢性関節リウマチの評価方法
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
JP2008539700A (ja) * 2005-05-04 2008-11-20 オーストラリアン ステム セル センター リミテッド 系統拘束された造血幹細胞の選択、培養および作出法
WO2007139164A1 (ja) 2006-05-31 2007-12-06 Astellas Pharma Inc. ヒト化抗ヒトオステオポンチン抗体
EP2025749A4 (en) * 2006-05-31 2009-12-16 Astellas Pharma Inc HUMANIZED ANTI-HUMAN-EASTOPONTIN ANTIBODY
US7807161B2 (en) 2006-05-31 2010-10-05 Astellas Pharma Inc. Humanized anti-human osteopontin antibody
EP2025749A1 (en) * 2006-05-31 2009-02-18 Astellas Pharma Inc. Humanized anti-human osteopontin antibody
KR101475960B1 (ko) * 2006-10-26 2014-12-23 가부시키가이샤 진 테크노 사이언스 세포외 매트릭스 단백질의 아미노산 서열 ｒｇｄ에 대한 항체 및 그의 제법과 용도
US8901280B2 (en) 2006-10-26 2014-12-02 Gene Techno Science Co., Ltd. Antibody against RGD in amino acid sequence of extracellular matrix protein and production method and use of the same
JP5399710B2 (ja) * 2006-10-26 2014-01-29 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに対する抗体およびその製法と用途
WO2008050907A1 (en) * 2006-10-26 2008-05-02 Gene Techno Science Co., Ltd. Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same
US20100317587A1 (en) * 2007-06-05 2010-12-16 Seoul National University Industry Foundation Injectable bone regeneration gel containing bone formation enhancing peptide
US8546529B2 (en) * 2007-06-05 2013-10-01 Nano Intelligent Biomedical Engineering Corporation Co., Ltd. Injectable bone regeneration gel containing bone formation enhancing peptide
JP2014223079A (ja) * 2007-07-13 2014-12-04 バク アイピー ベスローテン フェンノートシャップ 哺乳動物ＩｇＧと結合する単一ドメイン抗原結合タンパク質
US10259886B2 (en) 2007-07-13 2019-04-16 Bac Ip B.V. Single-domain antigen-binding proteins that bind mammalian IgG
WO2009088064A1 (ja) 2008-01-11 2009-07-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 改良型ヒト化抗ヒトα９インテグリン抗体
US8603476B2 (en) 2008-01-11 2013-12-10 Astellas Pharma Inc. Humanized anti-human α9-integrin antibody
KR20100110852A (ko) * 2008-01-11 2010-10-13 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 개량형 인간화 항-인간 α9 인테그린 항체
KR101634636B1 (ko) 2008-01-11 2016-06-29 아스텔라스세이야쿠 가부시키가이샤 개량형 인간화 항-인간 α9 인테그린 항체
WO2009088065A1 (ja) 2008-01-11 2009-07-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト化抗ヒトα９インテグリン抗体
US8614296B2 (en) 2008-04-24 2013-12-24 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
WO2009131256A1 (en) * 2008-04-24 2009-10-29 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
AU2009238897B2 (en) * 2008-04-24 2015-03-19 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
KR101746861B1 (ko) 2008-04-24 2017-06-14 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 ｒｇｄ에 특이적인 인간화된 항체 및 그의 용도
JP2011519547A (ja) * 2008-04-24 2011-07-14 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに特異的なヒト化抗体およびその使用
WO2011037271A1 (en) * 2009-09-24 2011-03-31 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
US8617829B2 (en) 2009-09-24 2013-12-31 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof

Also Published As

Publication number Publication date
MXPA04002837A (es) 2005-11-04
US7241873B2 (en) 2007-07-10
EP1431310A4 (en) 2005-03-23
AU2002332290B2 (en) 2007-11-08
PL369446A1 (en) 2005-04-18
NZ531818A (en) 2005-10-28
RU2305111C2 (ru) 2007-08-27
KR20040048899A (ko) 2004-06-10
CN100352844C (zh) 2007-12-05
HUP0402049A3 (en) 2009-04-28
NO20041225L (no) 2004-05-25
CN1688604A (zh) 2005-10-26
US20060002923A1 (en) 2006-01-05
JPWO2003027151A1 (ja) 2005-01-06
RU2004112540A (ru) 2005-04-20
CA2461529A1 (en) 2003-04-03
HUP0402049A2 (hu) 2005-01-28
HK1084127A1 (en) 2006-07-21
EP1431310A1 (en) 2004-06-23
BR0213078A (pt) 2004-11-23

Similar Documents

Publication Publication Date Title
WO2003027151A1 (fr) Anticorps recombinant anti-osteopontine et son utilisation
WO2002081522A1 (fr) Anticorps dirigé contre l'ostéopontine, et son utilisation
EP2277917A3 (en) B7-H3L cell surface target and a family of antibodies recognizing that target
EP1461428A4 (en) HYBRID ANTIBODIES
WO2005000897A3 (en) Antibodies against interleukin-22 and uses therefor
WO2004108889A3 (en) Hybrid antibodies
IN2009KN02655A (ja)
WO2002058717A3 (en) Methods for treating rheumatoid arthritis using il-17 antagonists
DE69635406D1 (de) Chemokinrezeptor 88c sowie dessen antikörper
WO2005003171A3 (en) Modified antibody fragments
ZA945753B (en) Bispecific trigger molecules recognizing lymphocyte antigen CD2 and tumor antigens
WO2003030833A3 (en) Angiopoietin-2 specific binding agents
MY144925A (en) Il-17 antagonistic antibodies
DE69737292D1 (de) Peptid abgeleitet von einem antigen das von antikörpern aus patienten mit rheumatoider arthritis erkannt wird, antikörper gegen dieses peptid und ein verfahren zum nachweis von autoimmunantikörpern
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
IL165364A0 (en) Method for obtaining anti-idiotype antibodies
WO2000078802A3 (en) Secreted polypeptides and corresponding polynucleotides
Mumma Increasing accuracy in clinical decision making: Toward an integration of nomothetic-aggregate and intraindividual-idiographic approaches.
WO2002008946A3 (en) A method and system for a document search system using search criteria comprised of ratings prepared by experts
WO2002010371A1 (fr) Peptide acitf sur le plan physiologique et utilisation de celui-ci
BRPI0415600A (pt) correia nervurada de transmissão de potência
WO2000070046A3 (en) Secreted polypeptides and corresponding polynucleotides
EP1270593A3 (en) HSCA-3 antigen and monoclonal antibody which recognizes the antigen
TH50175A (th) แอนติบอดีที่ต้าน Fas ของคนสำหรับใช้ในคน
WO2002081515A1 (fr) Proteine de liaison de facteur de croissance de type insuline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003530737

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002332290

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 00359/KOLNP/2004

Country of ref document: IN

Ref document number: 359/KOLNP/2004

Country of ref document: IN

Ref document number: 2002768058

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 531818

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2006002923

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2461529

Country of ref document: CA

Ref document number: 10489866

Country of ref document: US

Ref document number: 1020047004266

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/002837

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 20028234138

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002768058

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 531818

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 10489866

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 531818

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2002768058

Country of ref document: EP